HEM Insider Trading

Insider Ownership Percentage: 10.43%
Insider Buying (Last 12 Months): C$480.00
Insider Selling (Last 12 Months): C$23,719.48

Hemostemix Insider Trading History Chart

This chart shows the insider buying and selling history at Hemostemix by year and by quarter.

Skip ChartChart Data in Insider Trading History Table
2022202320242025C$0boughtC$0soldQ1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1-C$50kC$0C$50kTotal Insider BuyingTotal Insider Selling

Hemostemix Share Price & Price History

Current Price: C$0.31
Price Change: Price Increase of +0.035 (12.73%)
As of 01/17/2025 04:59 PM ET

This chart shows the closing price history over time for HEM up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365
FebMarAprMayJunJulAugSepOctNovDecJanC$0.31Closing price on 01/19/25:

Hemostemix Insider Trading History

See Full Table

SEC Filings (Institutional Ownership Changes) for Hemostemix (CVE:HEM)

Hemostemix logo
Hemostemix Inc., a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia. The company also develops NCP-01, which is preclinical trial to evaluate effect on neuropathic pain and motor function recovery. Hemostemix Inc. is headquartered in Calgary, Canada.
Read More on Hemostemix

Today's Range

Now: C$0.31
Low: C$0.27
High: C$0.31

50 Day Range

MA: C$0.11
Low: C$0.06
High: C$0.31

52 Week Range

Now: C$0.31
Low: C$0.04
High: C$0.31

Volume

825,985 shs

Average Volume

710,985 shs

Market Capitalization

C$27.01 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.2

Who are the company insiders with the largest holdings of Hemostemix?

Hemostemix's top insider shareholders include:
  1. Thomas Smeenk (Director)
Learn More about top insider investors at Hemostemix.